The purpose of the study is to see which medication provides better control of the disease after one year. Participants will receive their assigned medication regularly for up to 52 weeks, with scheduled doctor visits to check how they feel and to perform simple tests that look for signs of healing. The main goal is to determine whether patients achieve “deep remission,” meaning they have no symptoms and their intestinal lining looks normal.

The purpose of the study is to evaluate the one‑year effectiveness of guselkumab in real‑world patients with Crohn’s disease. Participants receive regular injections of the medication for up to twelve months and attend clinic visits at about 12, 24 and 48 weeks. During these visits doctors check how the patient feels, review stool tests that measure a protein called fecal calprotectin (a sign of gut inflammation), and look at the intestines using one of three imaging methods: an endoscopy (a thin camera inserted to see inside the gut), an MRI (a scan that uses magnets to create pictures of the body), or IUS (an ultrasound performed on the skin). Questions about quality of life are also completed to see if the treatment helps patients feel better overall.

The purpose of the study is to assess whether RO7790121 can help patients achieve clinical remission, which means a significant reduction in disease activity, and an endoscopic response, which refers to visible improvements in the digestive tract as seen through an endoscope. Participants in the study will receive either the treatment or a placebo, and their progress will be monitored over time to see how well the treatment works in reducing symptoms and improving their condition.

Throughout the study, researchers will track various outcomes, such as the overall change in symptoms, the severity of symptoms, and the general well-being of participants. They will also monitor any adverse events, which are unwanted effects that might occur during the trial. The study aims to provide valuable information on the potential benefits and risks of using RO7790121 for treating Crohn’s Disease, helping to improve future treatment options for those affected by this condition.

The purpose of this study is to assess how well Guselkumab works and how safe it is for people with moderately to severely active Crohn’s Disease. Participants in the study will receive either Guselkumab or a placebo. The study will last for several weeks, during which participants will receive regular injections and attend follow-up visits to monitor their health and the effects of the treatment.

Throughout the study, researchers will look for signs of improvement in the participants’ symptoms and check for any side effects. The main goal is to see if Guselkumab can help achieve clinical remission, which means a significant reduction or disappearance of symptoms, and an endoscopic response, which is an improvement seen during an examination of the digestive tract. The study aims to provide valuable information about the potential benefits of Guselkumab for people living with Crohn’s Disease.

The purpose of the study is to determine how safe Vedolizumab is when used over a long period in children who have these conditions. Participants in the study will receive regular infusions of Vedolizumab and will be monitored by healthcare professionals to check for any side effects or changes in their health. The study will also look at how the medication affects the growth and development of the children, as well as their overall well-being.

Throughout the study, researchers will collect information on any health events that occur while the children are receiving the treatment. This will help to understand the safety profile of Vedolizumab in young patients with Ulcerative Colitis or Crohn’s Disease. The study aims to provide valuable insights into the long-term use of this medication in managing these chronic conditions in children.

Participants in the study will receive mirikizumab through a subcutaneous injection, which is a method of delivering medication into the fatty layer of tissue just under the skin. During the course of the study, levels of the drug will be measured in breast milk to understand how much of the substance is present.

The purpose of the study is to determine the effect of ORG-129 on the levels of midazolam and its metabolite, which is a substance created when the body breaks down a drug. During the study, participants will receive the medications in a specific sequence. Monitoring will include checking vital signs, such as blood pressure and heart rate, as well as conducting physical exams and laboratory tests to ensure safety and observe the effects of the substances on the body.

During the study, patients will receive mirikizumab treatment over a period of up to 15 months for the injection forms and 3 months for the infusion form. The study will use imaging techniques such as MRI, which stands for magnetic resonance imaging and creates detailed pictures of the inside of the body, to measure changes in intestinal inflammation. Doctors will assess transmural response by looking at whether there is at least a 25% decrease in inflammation scores in affected segments of the intestine from the start of the study to week 24. The study will also evaluate whether patients achieve clinical remission, which means their symptoms have significantly improved or disappeared, and whether this improvement occurs together with the reduction in intestinal wall inflammation.

Throughout the study, researchers will monitor various aspects of the disease and treatment response at different time points including weeks 4, 8, 12, and 24. They will assess bowel damage, clinical symptoms, biochemical markers in the blood, and how well patients tolerate the medication. The study will also evaluate quality of life measures and track any unwanted effects or serious unwanted effects that may occur during treatment. Additional imaging with ultrasound may be used at certain visits to check for changes in intestinal inflammation.

The study aims to evaluate how safe and effective tulisokibart is when used over an extended period. The medication is given as a subcutaneous injection using a pre-filled injector device that delivers the medicine under the skin. Some participants will receive tulisokibart, while others will receive placebo through the same type of injection device.

The study will last for approximately 364 days (one year), during which participants will receive regular treatments and undergo various medical assessments. This extension study is specifically designed for people who have previously participated in earlier studies of tulisokibart and have shown benefit from the treatment. Throughout the study, doctors will monitor participants’ health and how well their digestive condition responds to the continued treatment.

During the study, researchers will monitor levels of a specific substance, MTX-PG, in the red blood cells. This substance is a byproduct of the medication that stays in the blood and can indicate how much medicine is actually active in the body. Participants will undergo regular check-ups to track their health and the effectiveness of the treatment over several months.

The research focuses on how different doses of the medication affect people over an extended period. During the course of the study, the way the body reacts to the treatment and any potential side effects will be monitored to ensure safety and how well the body tolerates the drug.

The purpose of the study is to evaluate the use of 68Ga-FAPI-46 to detect scar tissue inside the body. This substance is a radiopharmaceutical, which is a specialized drug used for medical imaging. Participants will undergo a PET/CT scan, a method that combines two types of imaging to create detailed pictures of the body’s internal structures. During the process, the substance is administered through an intravenous injection, meaning it is delivered directly into a vein.

Throughout the study, the imaging results will be compared with biological samples to see how well the scan identifies certain markers of scarring. Researchers will also look at how the substance moves through the body and how it can be used to better understand the progression of these diseases. This information may help in finding new ways to diagnose or treat scarring in the future.

Participants in the study will receive either duvakitug or a placebo through a subcutaneous injection, which is a shot administered just under the skin. This is a randomized study, meaning participants are assigned to a group by chance, and it is double-blind, meaning neither the participants nor the researchers know which treatment is being given. The study involves monitoring the condition over a period of time to observe how the body responds to the medication.

Participants in the study will receive either duvakitug or a placebo through a subcutaneous injection, which is a method of delivering medication just under the skin. This is an induction study, meaning the goal is to determine how well the treatment can quickly reduce active symptoms and inflammation. The study uses a randomized and double-blind approach, which means participants are assigned to groups by chance, and neither the participants nor the researchers know which specific treatment is being administered during the course of the study.

The study involves healthy participants who will receive the radioactive tracer during the research. After the tracer is given, special imaging scans called positron emission tomography or PET scans will be performed to track where the tracer travels in the body and how it binds to the CCR9 protein in different areas, particularly in the abdomen. The maximum amount of the tracer that will be given is very small, measured in micrograms, and the treatment period can last up to 60 days.

During the study, participants will undergo PET examinations to measure how much of the tracer is present in different regions of interest in the body. The researchers will calculate values that show how much of the tracer has accumulated in these areas and compare measurements between different PET scans. The study will also monitor any safety concerns or unwanted effects that may occur during the research. This research helps scientists understand how the tracer behaves in the body, which may be useful for future medical applications related to Crohn’s disease.

The purpose of this study is to measure how much of the medicine gets into the bloodstream when the capsule is opened and sprinkled on applesauce, strawberry jam, or yoghurt compared to swallowing the capsule whole without food, and also to see how eating food affects the amount of medicine that gets into the bloodstream when the capsule is swallowed whole. This information is important for understanding different ways the medicine can be taken, especially for people who may have difficulty swallowing capsules. The study will involve healthy adult participants who will receive a 30 mg dose of the medicine in different ways during the study.

Participants will take part in a study where they will receive the medicine in different forms on different occasions, allowing researchers to compare how the body processes the medicine under various conditions. Blood samples will be collected to measure the amount of medicine in the bloodstream over time. The study will monitor participants for any unwanted effects that may occur during the treatment period.

The purpose of this study is to check if gadopiclenol works well for finding and tracking perianal fistulas when used during magnetic resonance imaging, which is also called MRI, a type of scan that uses magnets and radio waves to create detailed pictures of the inside of the body. Participants will receive both contrast agents at different times during the study, with each one being given through a vein before an MRI scan is performed. The study follows a crossover design, which means that each person will have scans with both contrast agents so that doctors can compare how well each one works in showing the fistula tract, which is the path or tunnel of the abnormal connection.

During the study, doctors will look at the MRI images to see how clearly they can identify the perianal fistula when each contrast agent is used. They will also measure technical aspects of the images, such as how much difference there is between the fistula and the healthy tissue around it, and how much the contrast agent brightens the fistula area compared to before it was given. This information will help determine if gadopiclenol is as effective as gadobutrol for this specific use in people with Crohn’s disease and perianal fistulas.

The study is divided into different phases to test how well the medication works. In the first phase, called the induction phase, the goal is to see if icotrokinra can help reduce symptoms and improve the condition of the intestines after about 12 weeks of treatment. The study will look at whether participants have fewer symptoms and whether the inflammation in their intestines has improved. In the second phase, called the maintenance phase, participants who responded well to the treatment will continue to receive either icotrokinra or placebo for a longer period, up to about 40 weeks. This phase will check if the medication can help keep the disease under control over time and prevent symptoms from coming back.

Participants in this study must be adults who have been diagnosed with Crohn’s Disease for at least 12 weeks before joining the study. They need to have active disease with symptoms such as frequent loose stools or abdominal pain, and this must be confirmed by an examination of the intestines that shows inflammation and ulcers. Participants should have previously tried other treatments for Crohn’s Disease, such as steroids or other medications including biologics, but these treatments either did not work well enough, stopped working over time, or caused problems that made them difficult to tolerate. The study will last several years and will involve regular visits to monitor how well the treatment is working and to check for any side effects.

The main goal of this research is to determine if MT-501 is safe and effective for people with moderate to severe forms of these digestive conditions. The study is designed as a Phase 2 platform study, which means it will evaluate multiple treatment approaches for inflammatory bowel disease.

During the study, participants will go through an induction phase where they will take the study medication. Throughout this period, doctors will monitor how well the treatment works by examining the inside of the digestive tract and tracking symptoms. They will also check how the body processes the medication and look for any side effects that may occur. The study will collect information about improvements in the condition of the digestive tract lining and overall disease symptoms.

The medication will be administered as a solution for injection containing 108 mg of vedolizumab. During the study, participants will receive regular injections of the medication for up to 24 months. The study will monitor how well children and teenagers tolerate long-term treatment with vedolizumab and track any side effects that may occur.

Throughout the study, doctors will watch for any health-related events and track the effectiveness of the treatment. They will pay special attention to how the medication affects the participants’ daily lives and overall well-being. The study includes regular check-ups to monitor the participants’ health and assess how well the digestive conditions are being controlled by the treatment.

The study will use different combinations of these medications. Some participants will receive both mirikizumab and tirzepatide, while others will receive mirikizumab and a placebo. Both medications are given as injections under the skin, except in some cases where mirikizumab may be given through a vein. The treatment will continue for 52 weeks, which is approximately one year.

The study will measure how well the medications work together to achieve three main goals: reducing Crohn’s Disease symptoms, healing the inside of the digestive tract, and helping participants lose weight. The amount of tirzepatide used in the study may be adjusted up to 15 milligrams, depending on how well it is tolerated.

The study will test tulisokibart against placebo to see if it can help patients achieve remission, which means a significant reduction in disease symptoms. The medication will be given in two different ways: through intravenous infusion (delivered directly into a vein) or through subcutaneous injection (given under the skin using a pre-filled injector).

During the study, participants will receive treatment for 12 weeks. The researchers will monitor various aspects of the disease, including changes in symptoms such as abdominal pain and stool frequency. They will also examine the inside of the digestive tract to check if the treatment reduces inflammation and helps heal the intestinal lining. Throughout the study, participants will have regular check-ups to monitor their health and any potential side effects.

The study compares SAR442970 with placebo in patients who have not responded well enough to previous treatments. The medication or placebo will be administered through subcutaneous injections, which means the medicine is given under the skin. The maximum daily dose of the medication will be 150 milligrams, with a total maximum dose of 300 milligrams over the course of treatment.

The treatment period lasts for 52 weeks, during which patients will receive either the study medication or placebo. Throughout the study, doctors will monitor the condition of the intestinal lining and track various symptoms of Crohn’s disease. They will also check how safe the medication is and how well patients tolerate it. Participants will have regular check-ups to assess their response to treatment and monitor for any side effects.

The purpose of the study is to evaluate the effectiveness of FMT as a maintenance treatment for patients with Crohn’s disease who have been in remission without the use of steroids for at least six months. These patients have previously been treated with anti-TNF agents, which are medications that help reduce inflammation. The study will monitor participants over a period of 52 weeks to see if FMT can help maintain remission after stopping anti-TNF treatment.

Participants in the study will receive either the FMT treatment or a placebo. The FMT can be administered in different forms, such as an oral capsule or an enema, which is a liquid introduced into the rectum. The study will track the participants’ health and symptoms throughout the year to determine the success of the treatment. The goal is to see if FMT can help keep Crohn’s disease in remission without the need for additional medication.

Two treatments are being used in this study. The first is a product called Laxabon, which is a type of laxative that helps clear the bowel. It contains several substances, including sodium hydrogen carbonate, potassium chloride, sodium chloride, sodium sulfate anhydrous, and macrogol 3350. The second treatment is called Sonazoid, which is a dispersion for injection containing perflubutane. This is used to enhance the ultrasound images by providing a clearer view of the bowel’s interior.

The purpose of the study is to see how well these treatments work in providing a clear image of the bowel and to check for any side effects. Participants will undergo a procedure where they ingest the contrast, and doctors will use ultrasound to examine the bowel. The study will also look at how many participants are willing to undergo the procedure again and will compare findings between patients with Crohn’s disease and healthy volunteers. The study is expected to continue until the end of 2028.

The purpose of the study is to evaluate the safety of this treatment method. Participants will receive the treatment and be monitored over a period of six months. During this time, they will have regular check-ups to assess for any signs of infection or other complications. The study will also look at how well the treatment works in closing the fistulas and improving the participants’ quality of life. Assessments will be conducted at various intervals, including one week, one month, three months, and six months after the treatment is administered.

Throughout the study, participants will undergo evaluations using different methods, such as MRI scans, to check the healing progress of the fistulas. The study aims to provide valuable information on whether this innovative cell-based therapy can be a safe and effective option for individuals with Crohn’s disease who have not responded to other treatments.

The purpose of the study is to evaluate how well participants tolerate the medication over an extended period. Participants who have already shown a response to the treatment in previous trials will continue to take zasocitinib in capsule form. The study will last for up to 108 weeks, during which time participants will be monitored for any side effects or changes in their health. Some participants will receive a placebo, which is a substance with no active medication, to compare the effects of the actual drug.

Throughout the study, participants will have regular check-ups to assess their health, including monitoring vital signs and conducting laboratory tests. The study aims to gather information on the long-term effects of zasocitinib to better understand its safety and effectiveness in treating Ulcerative Colitis and Crohn’s Disease.

The purpose of this research is to determine how well RO7790121 works compared to placebo in helping patients maintain improvement of their Crohn’s Disease symptoms. The study involves two phases – an initial treatment phase (induction) followed by a longer maintenance phase where patients continue receiving either the study medication or placebo.

During the study, participants will receive regular doses of either RO7790121 or placebo through injections under the skin. The study is “double-blind,” which means neither the patients nor their doctors will know which treatment is being given. The effectiveness of the treatment will be measured by checking if patients achieve reduced disease activity and healing of the intestinal lining.

The purpose of the study is to find out if adjusting the doses of these medications based on regular monitoring of drug levels in the blood is as effective as the usual practice where the doctor decides the best dose. This approach is called Therapeutic Drug Monitoring (TDM). Participants in the study will receive either Vedolizumab or Ustekinumab, and their health will be monitored over a period of 48 weeks to see if the disease stays in remission, which means the symptoms are reduced or disappear.

Throughout the study, the researchers will also look at other factors, such as the cost of the treatments, the quality of life of the participants, and any changes in their health condition. The study aims to provide valuable information on the best way to use these medications to help people with Crohn’s disease and Ulcerative colitis manage their symptoms effectively.

The study will test SAR441566 against a placebo in the form of film-coated tablets. Participants will be randomly assigned to receive either the study medication or the placebo. The treatment period will last up to 104 weeks, during which doctors will monitor how well the medication works in reducing the signs and symptoms of Crohn’s Disease.

Throughout the study, doctors will assess how well the treatment improves the appearance of the intestinal lining during examinations and whether it helps reduce disease symptoms. They will also monitor participants’ overall well-being and check for any side effects that may occur during the treatment period. The medication will be taken by mouth according to a specific schedule determined by the study protocol.

Participants in the study will have been receiving vedolizumab every two weeks for at least six months and will be in a state of remission without the use of steroids. The study will explore whether it is possible to extend the time between doses without causing a relapse, which is when symptoms return. The trial will also look at various factors, such as the need for additional treatments like corticosteroids, the number of emergency visits, hospitalizations, surgeries, and any changes in the quality of life of the participants. Additionally, the study will assess the cost-effectiveness of extending the interval between doses and monitor any side effects that may occur.

The trial is expected to run for a period of time, with the recruitment of participants starting in early 2025 and the study concluding by the end of August 2026. The findings from this study could provide valuable insights into managing IBD more effectively and potentially improving the quality of life for those affected by these conditions.

The purpose of the study is to compare the effects of obefazimod with a placebo in managing Crohn’s disease symptoms. Participants will take the medication in the form of a hard capsule, which is taken orally. The study will be conducted in phases, including an induction phase to start the treatment, a maintenance phase to continue the treatment, and an extension phase to further evaluate safety and tolerability. The study will last for a period of up to 100 weeks, during which participants will have regular check-ups to monitor their health and the effects of the treatment.

Throughout the study, researchers will assess various aspects of the treatment, such as its ability to reduce disease activity and improve symptoms. They will also monitor for any side effects or adverse events to ensure the safety of the participants. The ultimate goal is to determine if obefazimod can be a beneficial treatment option for those living with Crohn’s disease.

The purpose of this study is to evaluate the safety and effectiveness of EXL01 in preventing the recurrence of Crohn’s disease after surgery. Participants in the study will be randomly assigned to receive either the EXL01 treatment or a placebo. The study will last for about six months, during which participants will take the treatment orally in capsule form. Throughout the study, participants will undergo regular check-ups and assessments to monitor their health and the progress of their condition.

The main goal is to compare the outcomes of those treated with EXL01 to those who receive the placebo, specifically looking at the recurrence of Crohn’s disease symptoms after surgery. This will be assessed using a method called endoscopy, which involves using a camera to look inside the digestive tract. The study aims to provide valuable information on whether EXL01 can help prevent the return of Crohn’s disease symptoms after surgery, potentially offering a new option for managing this challenging condition.

The purpose of the study is to compare the long-term effectiveness and safety of using periodic adalimumab as the first treatment for patients newly diagnosed with Crohn’s disease, against the standard approach of starting with medications like corticosteroids or budesonide. Participants in the study will receive either the new treatment or the standard treatment, and their progress will be monitored over time to see which approach works better in managing the disease.

The study will follow participants for a period of time to observe how well they respond to the treatment and to check for any side effects. The main goal is to see if patients can achieve remission, which means their symptoms are reduced or disappear, without needing corticosteroids. Other aspects being looked at include the overall health care costs, the total amount of corticosteroids used, and the impact on patients’ quality of life. The study aims to provide valuable information that could help improve treatment strategies for people with Crohn’s disease.

The purpose of this study is to explore the potential benefits of combining FMT with either infliximab or vedolizumab. Participants will receive either FMT combined with infliximab, FMT combined with vedolizumab, or one of the medications alone. The study will last for about 12 weeks, during which participants will receive treatments and have their health monitored regularly. The goal is to see if the combination of FMT with these medications can improve symptoms more effectively than the medications alone.

Throughout the study, researchers will assess various health indicators, such as the level of inflammation in the gut, overall quality of life, and any side effects experienced. The study aims to provide insights into whether this combined treatment approach can lead to better outcomes for patients with active ulcerative colitis. Participants will be closely monitored to ensure their safety and well-being during the trial.

The purpose of the study is to see if the combination of Vedolizumab and Upadacitinib can improve the health of people with moderately to severely active Crohn’s Disease more effectively than Vedolizumab alone. Participants will receive the treatment for a period of up to 52 weeks. Initially, both medications will be used together for a short period to see if they can quickly improve symptoms and the condition of the digestive tract. After this initial phase, the study will continue with Vedolizumab alone to maintain the improvements.

Throughout the study, participants will be monitored to assess their response to the treatment, focusing on both clinical symptoms and the condition of the digestive tract as seen through medical examinations. The study aims to provide valuable information on whether this dual therapy approach can offer better outcomes for individuals living with Crohn’s Disease.

The purpose of the study is to evaluate the safety and tolerability of AGMB-129 in patients with fibrostenotic Crohn’s disease. Participants will be randomly assigned to receive either AGMB-129 or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not biased. The study will take place over a period of time, with regular check-ups to monitor the participants’ health and any changes in their condition.

Throughout the study, various health assessments will be conducted, including checking for any side effects, performing clinical laboratory tests, and monitoring heart health through an electrocardiogram (ECG). The study will also look at how AGMB-129 is processed in the body and its effects on certain genes in the intestinal lining. The goal is to gather comprehensive information about the treatment’s safety and its potential benefits for people with fibrostenotic Crohn’s disease.

The purpose of the study is to assess how well risankizumab works and how safe it is for patients. Participants in the study will receive either risankizumab or a placebo through subcutaneous injections, which means the medication is injected under the skin. The study will monitor participants over a period of time to see if there is an improvement in their symptoms and overall health. The trial aims to find out if risankizumab can help achieve clinical remission, which means a significant reduction in disease activity, and if it can lead to an endoscopic response, indicating healing of the intestinal lining.

Throughout the study, participants will be closely observed to ensure their safety and to gather information on how the treatment affects their condition. The trial will also look at secondary outcomes, such as changes in fatigue levels and other symptoms related to Crohn’s disease. The findings from this study could provide valuable insights into the potential benefits of risankizumab for people living with Crohn’s disease.

The purpose of this study is to evaluate the safety and effectiveness of the combination of BI 706321 and ustekinumab over a period of 12 weeks. Participants will be randomly assigned to receive either the combination treatment or the placebo, along with ustekinumab. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not biased. The main goal is to see if the combination treatment can improve the condition of the digestive tract as observed through a procedure called endoscopy, which allows doctors to look inside the digestive tract.

Throughout the study, participants will have regular check-ups to monitor their health and any changes in their symptoms. The study will also look at how the body processes the medication and any potential side effects. By the end of the 12-week period, researchers hope to gather enough information to determine if the combination of BI 706321 and ustekinumab is a safe and effective treatment option for people with moderate to severe Crohn’s Disease. This trial is an important step in finding new ways to help manage this challenging condition.

Participants in the study will receive Vedolizumab through an intravenous infusion, which means the medication is given directly into a vein. The study will also involve a comparison with a placebo to assess the safety profile of Vedolizumab. Another medication, Prednisone, a type of corticosteroid, may also be used in the study. Prednisone is commonly used to reduce inflammation and suppress the immune system. The study will monitor participants for any adverse events or side effects that may occur during the treatment period.

The study will follow participants over a period of time to observe any long-term effects of Vedolizumab treatment. This includes tracking any major events related to inflammatory bowel disease, such as hospitalizations or surgeries, and assessing changes in health scores for participants aged 9 to 17 years. The goal is to ensure that Vedolizumab is safe for long-term use in managing Ulcerative Colitis and Crohn’s Disease in pediatric patients.